3 Things You Need to Know if You Buy Walgreens Stock Today
Walgreens is an iconic brand in the pharmacy space, but it has fallen on hard times.
The retailer has agreed to be taken private as it looks to turn its business around.
There's a potential post-takeover boost for shareholders, but the outcome is far from certain.
10 stocks we like better than Walgreens Boots Alliance ›
Walgreens Boots Alliance's (NASDAQ: WBA) stores dot the U.S. landscape, given that it is one of the largest pharmacy retailers in the country. But as an investment, well, it hasn't performed very well for a little while. And now it is heading into private hands. Here are three things you need to know before you buy Walgreens stock today.
1. Walgreens has been struggling
The most important thing to keep in mind when you look at Walgreens today is -- unfortunately-- its weak business performance. It really isn't unique to Walgreens; the entire pharmacy retail space has been kind of tough. However, Walgreens compounded the problem by making big investments that didn't pan out as well as hoped.
For example, it got into the pharmacy benefit management business only to realize that it wasn't going to be the growth engine management had hoped. It exited the space and pivoted into the emerging medical clinic niche. That, too, hasn't gone according to plan. Add in a bloated retail store base and the company is in need of a major overhaul.
It has been working toward that goal, but big revamps can be hard to do for public companies. For example, the decision to cut Walgreens' dividend to preserve cash was not well received by investors even though it will be helpful to the turnaround. Which brings the story to point number 2.
2. Walgreens is being taken private
Sometimes it helps for a company to be in private hands during a turnaround effort. That allows management to make bigger and bolder moves because it doesn't have to worry about appeasing Wall Street. To that end, Walgreens has agreed to be bought by Sycamore Partners. The deal is expected to close in the second half of 2025, with Walgreens shareholders getting $11.45 per share in cash.
That's all that investors here can expect to receive if they buy Walgreens. That's the guaranteed upside limit. Right now the stock is trading at a few cents above the takeout figure (more on this in a second). There's two big takeaways. First, Walgreens is not a long term investment because it is exiting the public market. Second, the guaranteed return here is basically zero (or worse) at this point. Sure, Walgreens is an iconic business, but it probably isn't the best investment choice for most.
3. There's a possible boost for investors
The wrinkle in this story is that Walgreens is actively looking to sell its medical clinic business. That sale will likely occur after it is taken private. And, as a sweetener for the deal, Sycamore Partners is giving shareholders a chit that entitles them to a portion of the proceeds from the sale of the clinic business. It could be worth as much as $3 per share. That could mean an additional 25% or so upside after the company goes private.
The problem with this is that there's no time frame for the clinic business sale. And there's no guarantee on the price, either. So investors could get $3 per share, or they could get nothing. They could get money the day after the Walgreens takeover closes, or they could never get any money. This is, at best, a special situation that only more aggressive investors will want to bother with. It seems likely that the clinic business has some value, but it is hard to assess what that value is or assign a time frame to the final payment, if there is one.
The Walgreens stock story is just about over, for now
Walgreens' run as a public company is about to end and, when that happens, the story here is largely over for investors. Yes, there's the potential sale of the clinic business, but the outcome there is so uncertain that the chance to benefit will only appeal to more aggressive investors. Over the long term, it is likely that Walgreens eventually finds its way back into the public markets. Hopefully, at that point, it will have revamped the business and again be working from a position of strength.
Do the experts think Walgreens Boots Alliance is a buy right now?
The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Walgreens Boots Alliance make the list?
When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,041% vs. just 183% for the S&P — that is beating the market by 858.71%!*
Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!*
The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of July 21, 2025
Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
3 Things You Need to Know if You Buy Walgreens Stock Today was originally published by The Motley Fool
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Bloomberg
4 minutes ago
- Bloomberg
OpenAI in Talks for Share Sale at $500 Billion Valuation
OpenAI is in early talks about a potential sale of stock for current and former employees at a valuation of about $500 billion, people briefed on the investment discussions said. The company is targeting a secondary stock sale in the billions of dollars, the people said, asking to remain anonymous because they weren't authorized to discuss the matter publicly. If the deal goes ahead, it would elevate OpenAI's on-paper price tag by roughly two-thirds. Its previous valuation stood at $300 billion in a $40 billion financing round led by SoftBank Group Corp. — making it one of the largest privately held companies in the world. Representatives for OpenAI and Thrive declined to comment. The company is also is providing access to its ChatGPT product to US federal agencies at a nominal cost of $1 a year as part of a push to get its AI chatbot more widely adopted. Shirin Ghaffary reports. (Source: Bloomberg)


Bloomberg
4 minutes ago
- Bloomberg
Trump, Apple to Announce Fresh $100 Billion US Investment
President Donald Trump plans to announce that Apple Inc. will commit to spending another $100 billion on domestic manufacturing, the latest pledge by the tech giant to increase US production of its products as it seeks to avoid punishing tariffs on its flagship iPhones. The announcement at the White House on Wednesday includes a new manufacturing program designed to bring more of Apple's supply chain to the US, with an eye toward assembling additional critical components domestically, according to a White House official who detailed the announcement on the condition of anonymity. Apple Chief Executive Officer Tim Cook is expected to attend the event. Bloomberg's Managing Editor for Global Consumer Tech Mark Gurman reports. (Source: Bloomberg)


Bloomberg
4 minutes ago
- Bloomberg
China's ‘National Team' Perfects the Art of Dip Buying
The stock market is not the economy. This year, other factors, such as retail participation in the US and corporate governance reform in South Korea, are pushing markets to tease record highs despite aweak economic reality. In China, a key catalyst is the involvement of the so-called ' national team,' a group of institutional investors that buys index funds to stem market routs. The main players include Central Huijin Investment Ltd., a domestic unit of the sovereign fund China Investment Corp., China Securities Finance Corp. and the Social Security Fund.